Cargando…

Debulking of Advanced Gastrointestinal Stromal Tumor With Peritoneal Carcinomatosis Refractory to Imatinib and Sunitinib: A Case Report

Gastrointestinal stromal tumors (GISTs) are non-epithelial stromal tumors that arise in the gastrointestinal tract. Pharmacological treatments for GIST are tyrosine kinase inhibitors. For metastatic disease, debulking may be helpful in reducing the tumor burden, thus increasing the effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rave, Talia E., Guerrero, Manrique A., Christian, Derick J., Zuberi, Jamshed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383614/ https://www.ncbi.nlm.nih.gov/pubmed/34434427 http://dx.doi.org/10.14740/jmc3598

Ejemplares similares

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Giant gastric gastrointestinal stromal tumor with severe peritoneal dissemination controlled by imatinib therapy following debulking surgery: a case report
por: Fukuda, Shuichi, et al.
Publicado: (2017)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours
por: Contreras-Hernández, I, et al.
Publicado: (2008)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
por: Rutkowski, Piotr, et al.
Publicado: (2012)

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study
por: Huang, Shaoqing, et al.
Publicado: (2023)

Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review
por: Xie, Fuming, et al.
Publicado: (2019)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Peritoneal Carcinomatosis as an Initial Presentation of Gastrointestinal Stromal Tumor: A Case Report and Review of the Literature
por: Ozcan, Gonca, et al.
Publicado: (2022)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
por: Harmon, Rhonda L, et al.
Publicado: (2005)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Leptomeningeal Carcinomatosis Secondary to a Gastrointestinal Stromal Tumor
por: Wlock, Rachel, et al.
Publicado: (2021)

Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
por: Hsu, Jun-Te, et al.
Publicado: (2017)

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
por: Son, Myoung Kyun, et al.
Publicado: (2017)

Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland
por: Brzozowska, Melania, et al.
Publicado: (2019)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
por: Qu, Hui, et al.
Publicado: (2022)

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
por: Hu, Xiangchen, et al.
Publicado: (2022)

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
por: Bauer, S, et al.
Publicado: (2014)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose
por: Hislop, Jennifer, et al.
Publicado: (2011)

Peritoneal Tuberculosis Mimicking Peritoneal Carcinomatosis
por: Akce, Mehmet, et al.
Publicado: (2014)

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
por: Chi, Ping, et al.
Publicado: (2022)

Peritoneal carcinomatosis mimicking a peritoneal tuberculosis
por: Jung, Eun Young, et al.
Publicado: (2015)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

CT mimics of peritoneal carcinomatosis
por: Smiti, S, et al.
Publicado: (2010)

An Unusual Case of Peritoneal Carcinomatosis
por: Hillewaere, Stijn, et al.
Publicado: (2010)

Lung cancer and peritoneal carcinomatosis
por: SERENO, MARÍA, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_so816s7km4slod5r3ic7up99lu